Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families.

Read more

Apr 02, 2019
Corium Appoints Perry Sternberg as Chief Executive Officer
MENLO PARK, Calif., April 2, 2019 (GLOBE NEWSWIRE) – Corium, Inc. announced today that its Board of Directors has named Perry Sternberg as Chief Executive Officer. Mr. Sternberg is a senior pharmaceutical executive with commercial experience across a wide range of therapeutic areas in diverse markets…


November 27, 2018
Gurnet Point Capital Announces Completion of Tender Offer
CAMBRIDGE, Mass., November 27, 2018 – Gurnet Point Capital (“Gurnet Point”), a private investment firm focused on the healthcare and life sciences sectors, announced today that it has completed the previously announced tender offer for all outstanding shares of common stock of Corium International, Inc. (Nasdaq: CORI) (“Corium”), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products….

OUR LEAD INVESTIGATIONAL PRODUCT

Corplex Donepezil

Our lead product is an investigational transdermal formulation of donepezil, the active ingredient in Aricept. Donepezil is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. Corplex Donepezil is designed to provide sustained and controlled delivery of donepezil. It is being investigated as a once-weekly treatment for Alzheimer’s disease to deliver either 5mg or 10mg of donepezil per 24 hours over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more

The safety and efficacy of Corplex Donepezil has not been established. There is no assurance that the product will receive health authority approval or become commercially available in any country.

circle_couple2